Teva Pharmaceutical Industries Ltd 8-K Filing
Ticker: TEVJF · Form: 8-K · Filed: Nov 5, 2025 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | Nov 5, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Teva Pharmaceutical Industries Ltd (ticker: TEVJF) to the SEC on Nov 5, 2025.
How long is this filing?
Teva Pharmaceutical Industries Ltd's 8-K filing is 2 pages with approximately 530 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2025-11-05 07:00:33
Filing Documents
- f8k_110525.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 464KB
- 0001171843-25-007000.txt ( ) — 713KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_110525_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 5, 2025, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference. The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Document 99.1 Teva Reports 2025 Third Quarter Financial Results 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: November 5, 2025 By: /s/ Eli Kalif Eli Kalif Executive Vice President, Chief Financial Officer